The Journal of Urology
Volume 166, Issue 6 , Pages 2185-2188 , December 2001

PREDICTING PROSTATE SPECIFIC ANTIGEN OUTCOME PREOPERATIVELY IN THE PROSTATE SPECIFIC ANTIGEN ERA

,Accepted 6 July 2001.

REFERENCES 

  1. Kupelian PA , Katcher J , Levin HS , et al.   Stage T1–2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy . Int J Radiat Oncol Biol Phys . 1997;137:1043
  2. D’Amico AV , Whittington R , Kaplan I . Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4–20 ng/ml . Int J Radiat Oncol Biol Phys . 1997;37:1053
  3. Zagars GK , Pollack A , Kavadi VS , et al.   Prostate-specific antigen and radiation therapy for clinically localized prostate cancer . Int J Radiat Oncol Biol Phys . 1995;32:293
  4. Pisansky TM , Kahn MJ , Rasp GM , et al.   A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma . Cancer . 1997;79:337
  5. Lee WR , Hanks GE , Schultheiss TE , et al.   Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen-driven outcome analysis . J Clin Oncol . 1995;13:464
  6. Pisansky TM , Cha SS , Earle JD , et al.   Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer . J Clin Oncol . 1993;11:2158
  7. Zietman AL , Coen JJ , Shipley WU , et al.   Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome . J Urol . 1994;151:640
  8. Hanks GE , Lee WR , Schultheiss TE . Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation . J Urol . 1995;154:456
  9. Partin AW , Piantadosi S , Sanda MG , et al.   Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy . Urology . 1995;45:831
  10. Lerner SE , Blute ML , Bergstralh EJ , et al.   Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy . J Urol . 1996;156:137
  11. Zietman AL , Edelstein RA , Coen JJ , et al.   Radical Prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome . Urology . 1994;43:828
  12. Kattan MW , Eastham JA , Stapelton AMF , et al.   A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer . J Nat Cancer Inst . 1998;90:766
  13. D’Amico AV , Whittington R , Schultz D , et al.   Outcome based staging for clinically localized adenocarcinoma of the prostate . J Urol . 1997;158:1422
  14. Ragde H , Blasko JC , Grimm PD . Interstitial 125iodine radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma . Cancer . 1997;80:442
  15. Blasko JC , Wallner K , Grimm PD , et al.   Prostate specific antigen based disease control following ultrasound guided I 125 implantation for stage T1/T2 prostatic carcinoma . J Urol . 1995;154:1096
  16. Wallner K , Roy J , Harrison L . Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma . J Clin Oncol . 1996;14:449
  17. Han M , Walsh PC , Partin AW , et al.   Ability of the 1992 and 1997 American Joint Commission on Cancer staging systems for prostate cancer to predict progression-free survival after radial prostatectomy for stage T2 disease . J Urol . 2000;164:89
  18. D’Amico AV , Whittington R , Malkowicz SB , et al.   Combined modality staging of prostate carcinoma and its utility in defining pathologic stage and postoperative prostate specific antigen failure . Urology, suppl . 1997;49:23
  19. D’Amico AV , Whittington R , Malkowicz SB , et al.   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer . JAMA . 1998;280:969
  20. Cox DR . Regression models and life tables . J Roy Stat Soc B . 1972;34:187
  21. Kaplan EL , Meier P . Non-parametric estimation from incomplete observations . J Amer Stat Assoc . 1958;53:457
  22. Vicini FA , Kestin LL , Martinez AA . The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer . Int J Radiat Oncol Biol Phys . 1999;45:553
  23. Pound CR , Partin AW , Eisenberger MA . Natural history of progression after PSA elevation following radical prostatectomy . JAMA . 1999;281:1591
  24. Sandler HM , Dunn RL , McLaughlin PW , et al.   Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy . Int J Radiat Oncol Biol Phys . 2000;48:629

 Presented at annual meeting of American Urological Association, Anaheim, California, June 2–7, 2001.

PII: S0022-5347(05)65531-0

The Journal of Urology
Volume 166, Issue 6 , Pages 2185-2188 , December 2001

Article Tools

* Image Usage & Resolution